Product Description
The U.S. dental bone graft substitute and other biomaterials market was valued at over $650 million in 2024. This is expected to increase over the forecast period at a CAGR of 6.8% to reach over $1.0 billion in 2031.
The full report suite on the U.S. market for dental bone graft substitutes (DBGSs) and other biomaterials includes dental bone graft substitutes, dental growth factors, dental barrier membranes, local antimicrobial periodontal treatments and dental soft tissue regeneration. Collectively, these segments will be referred to as the dental biomaterials market.
DATA TYPES INCLUDED IN THIS REPORT
- Unit Sales, Average Selling Prices, Market Size & Growth Trends
- Procedure Numbers
- Market Drivers & Limiters
- Market Forecasts Until 2031, and Historical Data to 2021
- Recent Mergers & Acquisitions
- Company Profiles and Product Portfolios
- Leading Competitors
U.S. DENTAL BONE GRAFT SUBSTITUTE MARKET TRENDS
The limited insurance coverage for dental implant and bone grafting procedures remains a significant barrier to the growth of the U.S. DBGS market. Most dental health insurance plans do not cover these treatments, leaving patients to bear significant out-of-pocket costs, discouraging many from pursuing periodontal or implant procedures. This financial limitation disproportionately affects economically disadvantaged populations, where the increased burden of cost significantly restricts access to dental care. Given that the growth of the DBGS market is closely tied to the increasing prevalence of dental implant procedures, broader insurance coverage for these treatments could incentivize a surge in access for both implant and bone grafting procedures. Such changes would not only improve patient accessibility but also drive sustained market growth by fostering greater procedural volume and demand for premium regenerative products.
U.S. DENTAL BONE GRAFT SUBSTITUTE MARKET SHARE INSIGHTS
- Geistlich established itself as the dominant player in the dental bone graft substitute and other biomaterials market in 2024, holding substantial shares of the dental bone graft substitute, dental barrier membrane and dental soft tissue regeneration segments. The company’s specialization in the regeneration of bone, cartilage and tissue has given it a notable competitive advantage in this market. Its products such as Bio-Oss®, Bio-Gide® and Mucograft® are widely recognized for their effectiveness and reliability, setting Geistlich apart from its competitors. In October 2022, Geistlich purchased Lynch Biologics and acquired the rights to Lynch’s GEM 21S®, one of the four dental growth factor products available in the United States. This acquisition further reinforced Geistilch’s position in the dental bone graft substitute market. With a continued emphasis on technological advancements in regenerative treatments, the company remains a dominant leader in this market.
- ZimVie, formerly Zimmer Biomet, was the second largest competitor in the dental bone graft substitute market in 2024. The company offers a broad portfolio that spans the dental bone graft substitute, dental barrier membrane and dental soft tissue regeneration segments. ZimVie has a comprehensive product catalog, entailing trusted brands and quality products that compete with top end dental bone graft products, such as its Puros® Allograft, Regeneross® line and IngeniOs® synthetic line. Its diverse and reputable offerings allow ZimVie to maintain a competitive edge in the market.
- OraPharma was the third-leading competitor in the dental biomaterials market in 2024, largely due to its strong presence in the local antimicrobial periodontal treatment market. This success is driven by its flagship product ARESTIN®. ARESTIN®(minocycline HCl) Microspheres, 1 mg, is used in combination with scaling and root planing (SRP) procedures to treat patients with adult periodontitis (gum disease). The product’s demonstrated effectiveness in enhancing periodontal treatment has reinforced OraPharma’s position as a dominant player in this market.
MARKET SEGMENTATION SUMMARY
- Dental Bone Graft Substitute Market – Further Segmented Into:
- Type: Mineralized Allograft, Demineralized Bone Matrix (DMB) Allograft, Xenograft, and Synthetics.
- Dental Growth Factor Market – Further Segmented Into:
- Product Type: Emdogain, Gem 215, Infuse, and Osteocels.
- Dental Barrier Membrane Market – Further Segmented Into:
- Type: Resorbable and Non-Resorbable Membranes.
- Local Antimicrobial Periodontal Treatment Market
- Dental Soft Tissue Regeneration Market – Further Segmented Into:
- Type: Regeneration and Wound Care.
RESEARCH SCOPE SUMMARY
| Report Attribute | Details |
|---|---|
| Regions | United States |
| Base Year | 2024 |
| Forecast Period | 2025-2031 |
| Historical Data | 2021-2023 |
| Quantitative Data | Procedure Numbers, Market Size, Market Shares, Market Forecasts, Market Growth Rates, Units Sold, and Average Selling Prices. |
| Qualitative Data | Market Growth Trends, Market Limiters, Competitive Analysis & SWOT for Top Competitors, Mergers & Acquisitions, Company Profiles, Product Portfolios, FDA Recalls, Disruptive Technologies, Disease Overviews. |
| Data Sources | Primary Interviews with Industry Leaders, Government Physician Data, Regulatory Data, Hospital Private Data, Import & Export Data, iData Research Internal Database. |
CONTACT US FOR ADDITIONAL INFORMATION
For full segmentation and any questions regarding research coverage, please contact us for a complimentary demo of the full report.
